bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract ED05-03: Surgical management of Stage I TN and HER2+ breast cancer
Authors: Mamtani A. 
Published: May 2024

Abstract
The management of early-stage triple-negative (TN) and HER2-positive (HER2+) breast cancer has evolved significantly with continually improving systemic therapies. The use of neoadjuvant chemotherapy (NAC) has become standard for stage II disease, for both surgical downstaging and assessment of response to treatment, allowing for tailoring of systemic therapy in the adjuvant setting. However, the optimal treatment approach for stage I TN and HER2+ disease remains controversial, given the limited burden of disease at presentation with most patients considered candidates for limited surgery, and the excellent overall outcomes with de-escalated systemic therapy regimens in the adjuvant setting. This presentation will discuss the evolving landscape and current standards for stage I TN and HER2+ disease.
Citation Format: A. Mamtani. Surgical management of Stage I TN and HER2+ breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr ED05-03.
Abstract ED11-01: Is inflammatory breast cancer a genomically different type of breast cancer?
Authors: Howard F. 
Published: May 2024

Abstract
Inflammatory Breast Cancer (IBC) is a unique and aggressive disease, constituting 2 - 4% of breast cancer diagnoses yet responsible for up to 10% of breast cancer related deaths. IBC remains a clinical diagnosis, without highly specific molecular markers, and the genomic drivers of the disease are incompletely characterized. The overrepresentation of human epidermal growth factor 2 amplification and triple-negative disease within IBC have confounded comparisons between IBC and non-IBC. Nonetheless, some consistent genomic observations have emerged that may begin to explain the characteristic behavior of IBC, supported by both comparative clinical studies and preclinical models. This session will review mutational analysis, gene expression profiling, and epigenetic findings that highlight similarities as well as subtle differences between IBC and non-IBC.
Citation Format: F. Howard. Is inflammatory breast cancer a genomically different type of breast cancer? [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr ED11-01.
Abstract PO1-04-04: Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial
Authors: Huang Xiang , Jin Nan , Sun Chunxiao , Yan Xueqi , Yang Fan , Liang Yan , Li Wei , Yin Yongmei 
Published: May 2024

Abstract
Aim: The efficacy and safety of inetetamab in combination with pyrotinib and oral vinorelbine was investigated in patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Methods: In this prospective, single-arm, phase 2 trial, patients with HER2-positive metastatic breast cancer after progression on trastuzumab were recruited. Patients received combined treatment of inetetamab (loading dose of 8 mg/kg, subsequent doses 6 mg/kg, intravenously once every 3 weeks) plus pyrotinib (400 mg orally once daily) plus vinorelbine (60 mg/m2 orally once weekly) until disease progression or intolerable toxicity. The primary endpoint was progression free survival (PFS). Secondary endpoints included objective response rate (ORR), overall survival (OS), disease control rate (DCR) and safety. The study was retrospectively registered in ClinicalTrials.gov on March 23rd, 2023. The registration number is NCT05823623. Results: Between Jan 1, 2022, and Dec 31, 2022, thirty patients were screened and enrolled to this study. The patients’ median age at enrollment was 54 years, twelve patients (40.0%) had hormone receptor-positive disease and 23 patients (76.7%) had visceral metastasis. The median PFS was 8.63 months (95% confidence interval [CI] 4.15 to 13.12 months). ORR was 53.3% (16/30) and DCR reached 96.7% (29/30). The most common grade III/IV adverse events included leukopenia (5[16.7%]), neutropenia (4[13.3%]) and diarrhea (3[10%]). No treatment-related serious adverse events or treatment-related deaths occurred. Conclusions: The combination regimen of inetetamab plus pyrotinib plus oral vinorelbine showed an encouraging efficacy and favorable safety in patients with HER2 positive metastatic breast cancer.
Citation Format: Xiang Huang, Nan Jin, Chunxiao Sun, Xueqi Yan, Fan Yang, Yan Liang, Wei Li, Yongmei Yin. Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-04-04.
Abstract PO1-07-04: Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer
Authors: Wang Han , Ding Xiao-Hong , Liu Cheng-Lin , Xiao Yi , Shui Ruo-Hong , Li Yan-Ping , Chen Chen , Yang Wen-Tao , Shao Zhi-Ming , Jiang Yi-Zhou 
Published: May 2024

Abstract
Background: Tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) remain controversial in predicting clinical outcomes of triple-negative breast cancer (TNBC), as outcomes do not always correlate with the expression of these biomarkers. Genomic and transcriptomic alterations that might contribute to the expression of these biomarkers remain incompletely uncovered. Methods: We evaluated PD-L1 immunohistochemistry (IHC) scores (SP142 and 28-8) and TILs in our TNBC multiomics dataset and two immunotherapy clinical trial cohorts. Then, we analyzed genomic and transcriptomic alterations correlated with TILs, PD-L1 expression and patient outcomes. Results: Despite TILs serving as a decent predictor for TNBC clinical outcomes, there remained exceptions. Our study revealed that several genomic alterations were correlated with unexpected events. Particularly, PD-L1 expression may cause a paradoxical relationship between TILs and prognosis in certain patients. Consequently, we classified TNBCs into four groups based on PD-L1 and TIL levels. The TIL-PD-L1+ and TIL+PD-L1- groups were not typical “hot” tumors; both were associated with worse prognoses and lower immunotherapy efficacy than TIL+PD-L1+ tumors. Copy number variation of PD-L1 and oncogenic signaling activation were correlated with PD-L1 expression in the TIL-PD-L1+ group, whereas GSK3B-induced degradation might cause undetectable PD-L1 expression in the TIL+PD-L1- group. These factors have the potential to affect the predictive function of both PD-L1 and TILs. Conclusions: Several genomic and transcriptomic alterations may cause paradoxical effects among TILs, PD-L1 expression and prognosis in TNBC. Investigating and targeting these factors will advance precision immunotherapy for TNBC patients. Keywords: Triple-negative breast cancer, PD-L1 expression, Tumor-infiltrating lymphocytes, Multiomics, Immunotherapy
Citation Format: Han Wang, Xiao-Hong Ding, Cheng-Lin Liu, Yi Xiao, Ruo-Hong Shui, Yan-Ping Li, Chen Chen, Wen-Tao Yang, Zhi-Ming Shao, Yi-Zhou Jiang. Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-04.
Abstract PO1-07-08: Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic
Authors: Simon Alexis , Badachi Yasmina , Ropers Jacques , Laurent Isaura , Dong Lida , Da Maia Elisabeth , Bourcier Agnes , Canlorbe Geoffroy , Uzan Catherine 
Published: May 2024

Abstract
BACKGROUND: Full field optical coherence tomography combined to dynamic cell imaging (D-FFOCT) is a new, simple to use, nondestructive, quick technique than can provide sufficient spatial resolution to mimic histopathological analysis. The objective of this study was to evaluate diagnostic performance of D-FFOCT for one-stop rapid diagnosis breast clinic. METHODS: D-FFOCT was applied to fresh untreated breast and nodes biopsies. Four different readers (senior and junior radiologist, surgeon and pathologist) analyzed the samples without knowing final histological diagnosis or ACR classification. The results were compared to conventional processing and staining (Hematoxylin-eosin). RESULTS: A total of 217 biopsies were performed on 152 patients. There were 144 breast biopsies and 61 lymph nodes with 101 infiltrative cancers (49,27%), 99 benign lesions (48,29%), 3 ductal in situ carcinoma (1,46%) and 2 atypias (0,98%). The diagnostic performances results were as follow: sensitivity: 77% [0.7;0.82], specificity: 64% [0.58;0.71], PPV: 74% [0.68;0.78] and NPV: 75% [0.72;0.78]. A large images atlas was created as well as a diagnosis algorithm from the readers experience. CONCLUSION: D-FFOCT provides interesting results defining malignancy on fresh breast and nodes samples. By training with the diagnosis algorithm and the images atlas or by using machine learning, radiologists could obtain even better outcomes allowing quick detection of breast cancer and lymph node involvement.
diagnosis algorithm
Figure 1 Images in DCI and FFOCT
Two infiltrating cancer diagnosed on pathology (A,B). Focusing on cells (C). Normal galactophoric duct (D). Adenofibroma (E)
Citation Format: Alexis Simon, Yasmina Badachi, Jacques Ropers, Isaura Laurent, Lida Dong, Elisabeth Da Maia, Agnes Bourcier, Geoffroy Canlorbe, Catherine Uzan. Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-08.
Abstract PO1-08-05: Using the CTS5 Score to Predict Late Recurrence in Male and Female Estrogen Receptor-Positive Breast Cancer Patients: a SEER database analysis of 65,729 cases
Authors: Wang Fenhua , Ren Fang , Qian Jian , Xu Yunxia , Wu Jiayi , Zong Yu , Gu Xidong 
Published: May 2024

Abstract
Purpose: The Clinical Treatment Score post-5 years (CTS5) score is a prognostic prediction tool to predict the risk of late distant recurrence in postmenopausal women with estrogen receptor-positive (ER+) breast cancer. Here we aimed to evaluate the prediction role of CTS5 in male breast cancer patients using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: ER+ early male and female breast cancer patients from the SEER database 2010-2013 were included. Clinicopathological features and the CTS5 score between the gender groups were compared using chi-square test. Overall survival (OS) and breast cancer-specific survival (BCSS) were estimated by Kaplan-Meier plots and compared between the groups with Log-rank test and multivariate cox proportional hazard regression models was used to determine the relationship between the CTS5 score and breast cancer survival outcomes in different gender cohorts. Results: A total of 65,729 ER+ breast cancer patients were included in the study and 611 were men. Male breast cancer was more likely to be diagnosed later in life (&gt;50 years old, 87.1% vs 73.6%, p &lt; 0.001), with more aggressive biological features (grade Ⅱ 51.6% vs 47.2%, p &lt; 0.001; grade Ⅲ 37.8% vs 28.3%, p &lt; 0.001) , and higher tumor burden (stage Ⅱ 45.8% vs 32.9%, p &lt; 0.001, stage Ⅲ 17.5% vs 10.5%, p &lt; 0.001) when compared to female counterparts. More male patients were CTS5 intermediate- or high-risk than female patients (high 7.9% vs 6.3%, intermediate 41.1% vs 24.6%, low 51.1% vs 69.1%, p &lt; 0.001). Patients were divided into 0-5 year and &gt;5 year cohorts based on whether they had a BCSS event within 5 years. In the &gt;5 year cohort, patients with CTS5 high- or intermediate- risk had worse survival outcomes compared with low-risk cases in male and postmenopausal female patients but not in premenopausal female patients. In the 0-5 year cohort, the CTS5 score was not predictive for disease recurrence in male or postmenopausal patients. Conclusion: Male breast cancer patients were more likely to have aggressive tumors and worse survival outcomes. The CTS5 score could be applied to predict breast cancer-specific mortality risk beyond 5 years in male ER+ breast cancer patients.
Citation Format: Fenhua Wang, Fang Ren, Jian Qian, Yunxia Xu, Jiayi Wu, Yu Zong, Xidong Gu. Using the CTS5 Score to Predict Late Recurrence in Male and Female Estrogen Receptor-Positive Breast Cancer Patients: a SEER database analysis of 65,729 cases [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-08-05.
Abstract PO1-08-11: The survival rate of hereditary breast cancer in young women of Kazakh population
Authors: Kaidarova Dilyara , Omarbayeva Nazgul , Abdrakhmanova Aliya , Shatkovskaya Oxana , Omarov Dilyar 
Published: May 2024

Abstract
Background
The study focused on determining survival rates between breast cancer patients with various germinal mutations and those without mutations among Kazakh women. Methods
The study included 222 female patients of Kazakh ethnic group diagnosed with stage I-IV stage breast cancer at the age up to 40 years old. DNA samples were tested by next-generation sequencing on the MiSeq Illumina platform using Trusight Cancer kit for the analysis of 94 genes and 287SNPs. Information about dates of diagnosis and death retried from cancer registry system. Survival analyses were performed and compared mutation carriers and non-carriers subgroups. The 5-year survival was calculated using the Kaplan-Meier method. Results
Next generation sequencing test identified 11 various pathogenic mutations in 57(25.7%) of overall 222 patients. The 5-year survival analysis for mutation carriers were 72.1%and 82.1% for non-carriers, with no statistically significant difference(P0.232). When stratified by mutational type, the 5-year survival rates were 71.8% for BRCA1 carriers, 81.3% for BRCA2, 53.35% for TP53 and 50% for moderate risk gene PALB2 mutation. These findings suggest that mutations in certain genes may be associated with differences in survival outcomes. Conclusions
In breast cancer patients of Kazakh population similar to the world prevalence and predictive value of germline mutations have been found. A subcohort of mutation carriers and non-carriers demonstrated no significant difference in 5-year survival rate which may be associated with an early onset of disease, high-risk predictor of poor prognosis. Long-term survival and detailed PFS will be published according to information of follow-up visits and the cancer register system.
Citation Format: Dilyara Kaidarova, Nazgul Omarbayeva, Aliya Abdrakhmanova, Oxana Shatkovskaya, Dilyar Omarov. The survival rate of hereditary breast cancer in young women of Kazakh population [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-08-11.
Abstract PO1-12-01: 'Not even my husband knows that I have this [breast cancer]': Survivors’ Experiences in Accessing, Navigating and Coping with Treatment
Authors: Chidebe Runcie C.W. , Orjiakor Tochukwu C. , Okwu Gloria C. , Orji Mary-Gloria A. , Nwosu-Zita THEODORA , Agha Agha A. , Aruah Simeon C. , Okem-Akwiwu Chika , Nwakasi Candidus C. , Gyimah Akwasi Adjei , Shinkafi-Bagudu Zainab , Okoye Ifeoma J. , Esiaka Darlingtina K. 
Published: May 2024

Abstract
Purpose: Nigeria has the highest breast cancer (BC) burden in Africa. While the survival rates for BC are over 90% in many high-income countries; low-and middle-income countries like Nigeria have 40% BC survival rates. Prior studies show that the burden and poor BC survival rates are exacerbated by both health system and individual level factors, yet there is a paucity of literature on the experiences of BC survivors in Nigeria. Hence, this study explored BC survivors' divergent and convergent experiences in accessing, navigating, and coping with treatment.
Methods: Participants (N=24, aged 35 to 73 years) were recruited and engaged in focus group discussions (Group 1, n = 11; Group 2, n = 13 participants). Transcripts were transcribed verbatim and analyzed with inductive thematic analysis.
Results: Four themes were identified: “I am carrying this [breast cancer] alone”, “Living my life”, “‘God’ helped me”, and “A very painful journey”. Participants described how they concealed their BC diagnosis from family and significant others while accessing and navigating BC treatment. Also, they adopted spiritual beliefs as a coping mechanism while sticking to their treatment and acknowledging the burden of BC on their wellbeing.
Conclusions: Our findings point to the urgent need for improved BC treatment facilities in Nigeria.
Implications for Breast Cancer Survivors: Nigeria BC survivors are navigating both limited treatment facilities and coping with the personal challenges of BC diagnosis. There is a need for the government and clinicians to explore innovative technologies in improving BC treatment experiences in Nigeria.
Citation Format: Runcie C.W. Chidebe, Tochukwu C. Orjiakor, Gloria C. Okwu, Mary-Gloria A. Orji, THEODORA Nwosu-Zita, Agha A. Agha, Simeon C. Aruah, Chika Okem-Akwiwu, Candidus C. Nwakasi, Akwasi Adjei Gyimah, Zainab Shinkafi-Bagudu, Ifeoma J. Okoye, Darlingtina K. Esiaka. 'Not even my husband knows that I have this [breast cancer]': Survivors’ Experiences in Accessing, Navigating and Coping with Treatment [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-12-01.
Abstract PO1-15-08: Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy
Authors: Zhu Xiu-Zhi , Zhou Yi-Fan , Wang Yun-Yi , Ding Xiao-Hong , Jin Xi , Shao Zhi-Ming , Jiang Yi-Zhou , Wang Zhong-Hua 
Published: May 2024

Abstract
Background: While primary triple-negative breast cancer (TNBC) garners significant research attention, the genomic alterations that occur in metastasis remain insufficiently understood, especially within Asian populations. Furthermore, the genomic information obtained from the primary tumor inadequately guides metastatic cancer treatment, highlighting the critical need for in-depth investigations into metastatic TNBC. Methods: We constructed the largest cohort of TNBC metastases (n = 296) among advanced TNBC patients treated at Fudan University Shanghai Cancer Center (FUSCC) between October 2018 and December 2020. Comprehensive DNA sequencing was conducted on the collected metastatic samples to analyze genomic alterations associated with treatment response. The underlying mechanisms of specific biomarkers were also explored. Results: We presented the genomic landscape of 296 TNBC metastases, encompassing mutant genes, mutation sites and copy number variations. Through multidimensional analysis, significant disparities in TNBC were observed between Western and Asian populations, primary and metastatic tumors, as well as different metastatic sites. Notably, our findings underscore the importance of sequencing TNBC metastases to guide precision therapy, which was associated with longer progression-free survival compared to physician-chosen treatments, shedding light on the pivotal clinical value of genomic studies in metastatic settings. Furthermore, efficacy analysis suggested that PKD1 mutations enriched in metastases mediated resistance to immunotherapy. These findings were further validated through three clinical trials (NCT03805399, NCT04129996, and NCT04395989). Mechanistic studies unveiled the involvement of PKD1 in TNBC immune evasion by upregulating CCL2, thereby facilitating the recruitment of M2-type tumor-associated macrophages. Conclusion: Our study emphasizes the critical significance and necessity of genomic profiling of metastases in guiding precision therapy for TNBC. Moreover, our findings reveal PKD1 as a novel and promising biomarker for immunotherapy.
Citation Format: Xiu-Zhi Zhu, Yi-Fan Zhou, Yun-Yi Wang, Xiao-Hong Ding, Xi Jin, Zhi-Ming Shao, Yi-Zhou Jiang, Zhong-Hua Wang. Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-08.
Abstract PO1-18-02: Histologic grade is a better predictor of specific survival than Ki67 in localized ER+/HER2- breast cancer: a real-world study
Authors: SÁNCHEZ Cesar , Alejandro Cataldo , Walbaum Benjamin , ACEVEDO FRANCISCO , Constabel Christine , Saure Antoine , Rey Pablo 
Published: May 2024

Abstract
Introduction: Breast cancer (BC) is the most common cancer in women. The determination of prognostic factors is relevant for the decision of systemic therapy. Objective: To determine, in the real world, the prognostic role of Ki67 and histologic grade (HG) in patients with non-metastatic BC in two cancer centers; an academic and a community hospital. Methodology: Retrospective analysis of a longitudinal BC patients registry. Clinicopathological characteristics and disease specific survival (DSS) of women diagnosed in stages I/II/III between the years 2012-2021 were analyzed. Results: We evaluated 3,969 cases that met the inclusion criteria. In the univariate analysis, prognostic factors significantly associated with DSS were: reason for consultation (screening vs symptoms), stage, hormone receptor status, HG and Ki67. On multivariate analysis, stage III, Ki67 ≥20%, and GH3 were significantly associated with a risk of death of 4.41, 2.52, and 1.92; respectively, regardless of the treatment center and BC subtype. However, in the hormone receptor positive (HR+)/HER2 + group the HG presented greater discriminatory power than Ki67. Hazard ratio 2.0 for both, but not statistically significant for Ki67. The ROC-AUC curves for Ki67 indicated that the best cut-off point for DSS was 20%, for the entire cohort and also for the HR+/HER2- group. Conclusions: The behavior of the prognostic variables was expected and coincided with the literature. HG seems to be a better predictor of specific mortality in HR+ BC. Ki67 showed a cut-off value consistent with that suggested by expert consensus.
Citation Format: Cesar SÁNCHEZ, Cataldo Alejandro, Benjamin Walbaum, FRANCISCO ACEVEDO, Christine Constabel, Antoine Saure, Pablo Rey. Histologic grade is a better predictor of specific survival than Ki67 in localized ER+/HER2- breast cancer: a real-world study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-18-02.